Once-weekly Teriparatide Reduces the Risk of Vertebral Fracture in Patients with Various Fracture Risks: Subgroup Analysis of the Teriparatide Once-Weekly Efficacy Research (TOWER) Trial

Overview

Journal J Bone Miner Metab

Specialty Endocrinology

Date 2013 Nov 12

PMID 24213216

Citations 16

Authors

Tetsuo Nakano

Masataka Shiraki

Toshitsugu Sugimoto

Hideaki Kishimoto

Masako Ito

Masao Fukunaga

Hiroshi Hagino

Teruki Sone

Tatsuhiko Kuroda

Toshitaka Nakamura

Affiliations

Soon will be listed here.

Abstract

Once-weekly teriparatide (human parathyroid hormone [1-34]) (56.5 μg for 72 weeks) injections provided a vertebral fracture risk reduction in Japanese osteoporotic patients evaluated in the Teriparatide Once-Weekly Efficacy Research (TOWER) trial. Using data from the TOWER trial, a subgroup analysis was performed to study the efficacy of once-weekly teriparatide for a variety of baseline clinical risk factors in placebo (n = 281) and teriparatide (n = 261) groups. Significant fracture risk reductions were observed in the subgroups of individuals aged <75 years [relative risk (RR) 0.06, p = 0.007] and ≥75 years (RR 0.32, p = 0.015). A significant risk reduction was observed among patients with prevalent vertebral fracture in the subgroup with 1 (RR 0.08, p = 0.015) or ≥2 (RR 0.29, p = 0.009) prevalent vertebral fractures, and in those with grade 3 deformity (RR 0.26, p = 0.003). Significant risk reduction was observed in the subgroup with lumbar bone mineral density (BMD) < -2.5 SD (RR 0.25, p = 0.035). In the teriparatide group, no incident fracture was observed in the subgroups with a prevalent vertebral fracture number of 0, with grade 0-2 vertebral deformity, or with lumbar BMD ≥2.5 SD. Significant risk reduction was observed in all of the bone turnover marker and estimated glomerular filtration rate subgroups. In conclusion, once-weekly 56.5 μg teriparatide injection reduced the vertebral fracture risk in patients with varying degrees of fracture risk, age, vertebral fracture number and grade, bone turnover level, and renal function.

Citing Articles

Refracture following vertebral fragility fracture when bone fragility is not recognized: summarizing findings from comparator arms of randomized clinical trials.

Porcu G, Biffi A, Ronco R, Adami G, Alvaro R, Bogini R J Endocrinol Invest. 2023; 47(4):795-818.

PMID: 37921990 PMC: 10965723. DOI: 10.1007/s40618-023-02222-0.

Executive summary: Italian guidelines for diagnosis, risk stratification, and care continuity of fragility fractures 2021.

Corrao G, Biffi A, Porcu G, Ronco R, Adami G, Alvaro R Front Endocrinol (Lausanne). 2023; 14:1137671.

PMID: 37143730 PMC: 10151776. DOI: 10.3389/fendo.2023.1137671.

Fractures reduction with osteoporotic treatments in patients over 75-year-old: A systematic review and meta-analysis.

Guillaumin M, Poirson B, Gerazime A, Puyraveau M, Tannou T, Mauny F Front Aging. 2022; 3:845886.

PMID: 36404990 PMC: 9667050. DOI: 10.3389/fragi.2022.845886.

A quantitative analysis of bone lamellarity and bone collagen linearity induced by distinct dosing and frequencies of teriparatide administration in ovariectomized rats and monkeys.

Sato T, Takakura A, Lee J, Tokunaga K, Matsumori H, Takao-Kawabata R Microscopy (Oxf). 2021; 70(6):498-509.

PMID: 34100544 PMC: 8633100. DOI: 10.1093/jmicro/dfab020.

Efficacy of once-weekly and twice-weekly injections of teriparatide by patient characteristics: A post hoc analysis of the TWICE study.

Sugimoto T, Yoshimura T, Uzawa T Osteoporos Sarcopenia. 2021; 7(1):11-16.

PMID: 33869800 PMC: 8044588. DOI: 10.1016/j.afos.2020.12.001.

References

McClung M, Geusens P, Miller P, Zippel H, Bensen W, Roux C . Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. N Engl J Med. 2001; 344(5):333-40. DOI: 10.1056/NEJM200102013440503. View

Genant H, Jergas M, Palermo L, Nevitt M, Valentin R, Black D . Comparison of semiquantitative visual and quantitative morphometric assessment of prevalent and incident vertebral fractures in osteoporosis The Study of Osteoporotic Fractures Research Group. J Bone Miner Res. 1996; 11(7):984-96. DOI: 10.1002/jbmr.5650110716. View

Hallberg I, Bachrach-Lindstrom M, Hammerby S, Toss G, Ek A . Health-related quality of life after vertebral or hip fracture: a seven-year follow-up study. BMC Musculoskelet Disord. 2009; 10:135. PMC: 2776583. DOI: 10.1186/1471-2474-10-135. View

Kado D, Duong T, Stone K, Ensrud K, Nevitt M, Greendale G . Incident vertebral fractures and mortality in older women: a prospective study. Osteoporos Int. 2003; 14(7):589-94. DOI: 10.1007/s00198-003-1412-5. View

Cummings S, Black D, Thompson D, Applegate W, Barrett-Connor E, Musliner T . Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA. 1999; 280(24):2077-82. DOI: 10.1001/jama.280.24.2077. View

Neer R, Arnaud C, Zanchetta J, Prince R, Gaich G, Reginster J . Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med. 2001; 344(19):1434-41. DOI: 10.1056/NEJM200105103441904. View

Kaji H, Yamauchi M, Yamaguchi T, Shigematsu T, Sugimoto T . Mild renal dysfunction is a risk factor for a decrease in bone mineral density and vertebral fractures in Japanese postmenopausal women. J Clin Endocrinol Metab. 2010; 95(10):4635-42. DOI: 10.1210/jc.2010-0099. View

Miyauchi A, Matsumoto T, Sugimoto T, Tsujimoto M, Warner M, Nakamura T . Effects of teriparatide on bone mineral density and bone turnover markers in Japanese subjects with osteoporosis at high risk of fracture in a 24-month clinical study: 12-month, randomized, placebo-controlled, double-blind and 12-month open-label.... Bone. 2010; 47(3):493-502. DOI: 10.1016/j.bone.2010.05.022. View

Nakamura T, Sugimoto T, Nakano T, Kishimoto H, Ito M, Fukunaga M . Randomized Teriparatide [human parathyroid hormone (PTH) 1-34] Once-Weekly Efficacy Research (TOWER) trial for examining the reduction in new vertebral fractures in subjects with primary osteoporosis and high fracture risk. J Clin Endocrinol Metab. 2012; 97(9):3097-106. DOI: 10.1210/jc.2011-3479. View

10.

Cockerill W, Ismail A, Cooper C, Matthis C, Raspe H, Silman A . Does location of vertebral deformity within the spine influence back pain and disability? European Vertebral Osteoporosis Study (EVOS) Group. Ann Rheum Dis. 2000; 59(5):368-71. PMC: 1753132. DOI: 10.1136/ard.59.5.368. View

11.

Oleksik A, Lips P, Dawson A, Minshall M, Shen W, Cooper C . Health-related quality of life in postmenopausal women with low BMD with or without prevalent vertebral fractures. J Bone Miner Res. 2000; 15(7):1384-92. DOI: 10.1359/jbmr.2000.15.7.1384. View

12.

Ross P, Davis J, Epstein R, Wasnich R . Pre-existing fractures and bone mass predict vertebral fracture incidence in women. Ann Intern Med. 1991; 114(11):919-23. DOI: 10.7326/0003-4819-114-11-919. View

13.

Miller P, Schwartz E, Chen P, Misurski D, Krege J . Teriparatide in postmenopausal women with osteoporosis and mild or moderate renal impairment. Osteoporos Int. 2006; 18(1):59-68. DOI: 10.1007/s00198-006-0189-8. View

14.

Marcus R, Wang O, Satterwhite J, Mitlak B . The skeletal response to teriparatide is largely independent of age, initial bone mineral density, and prevalent vertebral fractures in postmenopausal women with osteoporosis. J Bone Miner Res. 2003; 18(1):18-23. DOI: 10.1359/jbmr.2003.18.1.18. View

15.

Gallagher J, Genant H, Crans G, Vargas S, Krege J . Teriparatide reduces the fracture risk associated with increasing number and severity of osteoporotic fractures. J Clin Endocrinol Metab. 2004; 90(3):1583-7. DOI: 10.1210/jc.2004-0826. View

16.

Imai E, Horio M, Nitta K, Yamagata K, Iseki K, Hara S . Estimation of glomerular filtration rate by the MDRD study equation modified for Japanese patients with chronic kidney disease. Clin Exp Nephrol. 2007; 11(1):41-50. DOI: 10.1007/s10157-006-0453-4. View

17.

Bouxsein M, Chen P, Glass E, Kallmes D, Delmas P, Mitlak B . Teriparatide and raloxifene reduce the risk of new adjacent vertebral fractures in postmenopausal women with osteoporosis. Results from two randomized controlled trials. J Bone Joint Surg Am. 2009; 91(6):1329-38. DOI: 10.2106/JBJS.H.01030. View

18.

Wustrack R, Seeman E, Bucci-Rechtweg C, Burch S, Palermo L, Black D . Predictors of new and severe vertebral fractures: results from the HORIZON Pivotal Fracture Trial. Osteoporos Int. 2011; 23(1):53-8. DOI: 10.1007/s00198-011-1664-4. View

19.

Wang R, Lagakos S, Ware J, Hunter D, Drazen J . Statistics in medicine--reporting of subgroup analyses in clinical trials. N Engl J Med. 2007; 357(21):2189-94. DOI: 10.1056/NEJMsr077003. View

20.

Nevitt M, Cummings S, Stone K, Palermo L, Black D, Bauer D . Risk factors for a first-incident radiographic vertebral fracture in women > or = 65 years of age: the study of osteoporotic fractures. J Bone Miner Res. 2004; 20(1):131-40. DOI: 10.1359/JBMR.041003. View